Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Naurex raises $18M to develop novel NMDA modulator in depression

This article was originally published in Scrip

Executive Summary

The start-up Naurex Inc has raised $18 million in a Series A financing to advance its CNS disorder candidates based on a new mechanism of action for modulating the NMDA receptor. It says that its lead clinical-stage candidate, GLYX-13, shows promise to achieve the well documented efficacy of known NMDA receptor modulating agents (like ketamine) for treatment-resistant depression, but without their limiting side effects. Notably, the round of venture backers includes both venture capital firms and pharma companies.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts